One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...

Join Bill Gates and a range of experts for a discussion on flattening barriers to improving women’s health — from research ...

New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...